Advanced search
1 file | 1.57 MB Add to list

Preclinical evaluation of TriMix and antigen mRNA-based anti-tumor therapy

(2012) CANCER RESEARCH. 72(7). p.1661-1671
Author
Organization
Abstract
The use of tumor-associated antigen (TAA) mRNA for therapeutic purposes is under active investigation. To be effective, mRNA vaccines need to deliver activation stimuli in addition to TAAs to dendritic cells (DC). In this study, we evaluated whether intranodal delivery of TAA mRNA together with TriMix, a mix of mRNA encoding CD40 ligand, constitutive active Toll-like receptor 4 and CD70, results in the in situ modification and maturation of DCs, hence, priming of TAA-specific T cells. We showed selective uptake and translation of mRNA in vivo by lymph node resident CD11c(+) cells. This process was hampered by codelivery of classical maturation stimuli but not by TriMix mRNA. Importantly, TriMix mRNA induced a T-cell-attracting and stimulatory environment, including recruitment of antigen-specific CD4(+) and CD8(+) T cells and CTLs against various TAAs. In several mouse tumor models, mRNA vaccination was as efficient in CTL induction and therapy response as vaccination with mRNA-electroporated DCs. Together, our findings suggest that intranodal administration of TAA mRNA together with mRNA encoding immunomodulating molecules is a promising vaccination strategy.
Keywords
ELECTROPORATED DENDRITIC CELLS, PATHWAYS, TOLL-LIKE RECEPTORS, CANCER-IMMUNOTHERAPY, GENETIC-MODIFICATION, IN-VIVO, VACCINATION, ACTIVATION, VACCINES, INDUCTION

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.57 MB

Citation

Please use this url to cite or link to this publication:

MLA
Van Lint, Sandra et al. “Preclinical Evaluation of TriMix and Antigen mRNA-based Anti-tumor Therapy.” CANCER RESEARCH 72.7 (2012): 1661–1671. Print.
APA
Van Lint, S., Goyvaerts, C., Maenhout, S., Goethals, L., Disy, A., Benteyn, D., Pen, J., et al. (2012). Preclinical evaluation of TriMix and antigen mRNA-based anti-tumor therapy. CANCER RESEARCH, 72(7), 1661–1671.
Chicago author-date
Van Lint, Sandra, Cleo Goyvaerts, Sarah Maenhout, Lode Goethals, Aurélie Disy, Daphné Benteyn, Joeri Pen, et al. 2012. “Preclinical Evaluation of TriMix and Antigen mRNA-based Anti-tumor Therapy.” Cancer Research 72 (7): 1661–1671.
Chicago author-date (all authors)
Van Lint, Sandra, Cleo Goyvaerts, Sarah Maenhout, Lode Goethals, Aurélie Disy, Daphné Benteyn, Joeri Pen, Aude Bonehill, Carlo Heirman, Karine Breckpot, and Kris Thielemans. 2012. “Preclinical Evaluation of TriMix and Antigen mRNA-based Anti-tumor Therapy.” Cancer Research 72 (7): 1661–1671.
Vancouver
1.
Van Lint S, Goyvaerts C, Maenhout S, Goethals L, Disy A, Benteyn D, et al. Preclinical evaluation of TriMix and antigen mRNA-based anti-tumor therapy. CANCER RESEARCH. 2012;72(7):1661–71.
IEEE
[1]
S. Van Lint et al., “Preclinical evaluation of TriMix and antigen mRNA-based anti-tumor therapy,” CANCER RESEARCH, vol. 72, no. 7, pp. 1661–1671, 2012.
@article{6963060,
  abstract     = {The use of tumor-associated antigen (TAA) mRNA for therapeutic purposes is under active investigation. To be effective, mRNA vaccines need to deliver activation stimuli in addition to TAAs to dendritic cells (DC). In this study, we evaluated whether intranodal delivery of TAA mRNA together with TriMix, a mix of mRNA encoding CD40 ligand, constitutive active Toll-like receptor 4 and CD70, results in the in situ modification and maturation of DCs, hence, priming of TAA-specific T cells. We showed selective uptake and translation of mRNA in vivo by lymph node resident CD11c(+) cells. This process was hampered by codelivery of classical maturation stimuli but not by TriMix mRNA. Importantly, TriMix mRNA induced a T-cell-attracting and stimulatory environment, including recruitment of antigen-specific CD4(+) and CD8(+) T cells and CTLs against various TAAs. In several mouse tumor models, mRNA vaccination was as efficient in CTL induction and therapy response as vaccination with mRNA-electroporated DCs. Together, our findings suggest that intranodal administration of TAA mRNA together with mRNA encoding immunomodulating molecules is a promising vaccination strategy.},
  author       = {Van Lint, Sandra and Goyvaerts, Cleo and Maenhout, Sarah and Goethals, Lode and Disy, Aurélie and Benteyn, Daphné and Pen, Joeri and Bonehill, Aude and Heirman, Carlo and Breckpot, Karine and Thielemans, Kris},
  issn         = {0008-5472},
  journal      = {CANCER RESEARCH},
  keywords     = {ELECTROPORATED DENDRITIC CELLS,PATHWAYS,TOLL-LIKE RECEPTORS,CANCER-IMMUNOTHERAPY,GENETIC-MODIFICATION,IN-VIVO,VACCINATION,ACTIVATION,VACCINES,INDUCTION},
  language     = {eng},
  number       = {7},
  pages        = {1661--1671},
  title        = {Preclinical evaluation of TriMix and antigen mRNA-based anti-tumor therapy},
  url          = {http://dx.doi.org/10.1158/0008-5472.CAN-11-2957},
  volume       = {72},
  year         = {2012},
}

Altmetric
View in Altmetric
Web of Science
Times cited: